Comparative Pharmacology
Head-to-head clinical analysis: STALEVO 200 versus STALEVO 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STALEVO 200 versus STALEVO 75.
STALEVO 200 vs STALEVO 75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
STALEVO 200 contains carbidopa, levodopa, and entacapone. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa availability to the brain. Levodopa is decarboxylated to dopamine in the brain, restoring dopaminergic activity in the striatum. Entacapone inhibits catechol-O-methyltransferase (COMT), reducing peripheral metabolism of levodopa and prolonging its half-life.
STALEVO 75 is a combination product containing carbidopa, levodopa, and entacapone. Levodopa is the metabolic precursor of dopamine, which crosses the blood-brain barrier and is converted to dopamine in the brain, thereby ameliorating dopamine deficiency in Parkinson's disease. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa availability to the brain. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), primarily in the periphery, which prolongs the plasma half-life of levodopa.
One tablet (levodopa 200 mg, carbidopa 50 mg, entacapone 200 mg) administered orally 3 to 4 times daily, adjusted based on response and tolerability.
Oral, 1 tablet (levodopa 75 mg, carbidopa 18.75 mg, entacapone 200 mg) taken 3 to 4 times daily. Maximum recommended dose: 10 tablets per day (levodopa 750 mg, carbidopa 187.5 mg, entacapone 2000 mg). Dose should be adjusted based on individual response and tolerability.
None Documented
None Documented
Levodopa: 1.3 hours (with carbidopa). Entacapone: 0.4-0.7 hours. Carbidopa: 1-2 hours. Terminal half-life of levodopa is extended to ~1.5-2 hours in combination; clinical dosing is every 4-6 hours.
Levodopa: 1.5-2 hours (alone). With carbidopa: 1.5 hours. Entacapone: 0.4-0.7 hours (elimination half-life). Clinical context: Entacapone prolongs levodopa half-life by ~30% via COMT inhibition.
Carbidopa: 70% renal (unchanged and metabolites), 30% fecal. Levodopa: 70-80% renal (metabolites), <10% fecal. Entacapone: 90% fecal (unchanged and metabolites), 10% renal.
Carbidopa: 70% renal (metabolites), 30% fecal. Levodopa: 80% renal (metabolites), 20% fecal. Entacapone: 90% fecal, 10% renal.
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent